ngm120
ngm120: sourced relationships with 1 company · 1 clinical trial tracked.
ngm120 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ngm120 → NGM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NGM BIOPHARMACEUTICALS INC (NGM) | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Primary endpoint: To Determine the Safety and Tolerability of NGM120 in Subjects
Frequently asked questions
Which companies have sourced relationships with ngm120?
ngm120 has dated SEC/FDA relationship records for NGM BIOPHARMACEUTICALS INC.
How many clinical trials involve ngm120?
BioSniper tracks 1 clinical trial involving ngm120.